Actively Recruiting
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Led by Everest Medicines (Beijing) Co., Ltd. · Updated on 2025-11-21
94
Participants Needed
7
Research Sites
310 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in patients with selected solid tumors.
CONDITIONS
Official Title
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a selected type of solid tumor that is pathologically confirmed as unresectable advanced, recurrent, or metastatic
- Have at least one tumor lesion that can be evaluated by investigators within 28 days before starting treatment
- Have an ECOG performance status of 0 or 1 at screening
- Have a life expectancy of at least 3 months
- Have adequate organ function
- Agree to provide tumor tissue for biomarker analysis if available; fresh biopsy is optional if archival tissue is not available and considered safe by the investigator
You will not qualify if you...
- Have a disease suitable for local treatment with curative intent
- Have had another malignancy diagnosed and/or treated within 5 years before starting treatment, except certain treated skin, bladder, breast, cervical, or prostate cancers
- Have nasopharynx cancer or non-squamous non-small cell lung cancer; presence of small cell elements excludes participation
- Have known active central nervous system metastases or carcinomatous meningitis
- Have a diagnosis of immunodeficiency
- Have used systemic corticosteroids over 10 mg/day prednisone or equivalent or other immunosuppressive drugs within 14 days before treatment
- Have active autoimmune disease requiring systemic treatment in the past 2 years or history of autoimmune disease with risk of relapse
- Have poorly controlled health conditions such as hypertension, type 2 diabetes, or active gastric or duodenal ulcers
- Have had cerebrovascular events within 6 months before treatment
- Have prolonged QTcF interval or serious cardiovascular disease within 6 months before treatment
- Have a left ventricular ejection fraction under 50% during screening
- Have a history of Stevens-Johnson syndrome or toxic epidermal necrolysis
- Are known to be HIV-positive or have AIDS
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10022
Actively Recruiting
2
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Not Yet Recruiting
3
NEXT Oncology
Fairfax, Virginia, United States, 22031
Actively Recruiting
4
Hunan Cancer Hospital
Changsha, Hunan, China, 410006
Not Yet Recruiting
5
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China, 210000
Not Yet Recruiting
6
The First Affiliated Hospital With Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Not Yet Recruiting
7
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200030
Not Yet Recruiting
Research Team
J
Jueying Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here